A fixed-dose combination ibuprofen and famotidine (Duexis)
- PMID: 22033211
A fixed-dose combination ibuprofen and famotidine (Duexis)
Erratum in
- Med Lett Drugs Ther. 2011 Nov 14;53(1377):92
Abstract
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo, a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.
© 2011 The Medical Letter, Inc.
Similar articles
-
HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):25-35. doi: 10.1586/egh.11.88. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22149579 Review.
-
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.N Engl J Med. 1996 May 30;334(22):1435-9. doi: 10.1056/NEJM199605303342204. N Engl J Med. 1996. PMID: 8618582 Clinical Trial.
-
Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.Clin Drug Investig. 2013 Sep;33(9):689-97. doi: 10.1007/s40261-013-0113-x. Clin Drug Investig. 2013. PMID: 23881568 Review.
-
Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.Clin Ther. 2013 Mar;35(3):321-32. doi: 10.1016/j.clinthera.2013.02.008. Clin Ther. 2013. PMID: 23497762
-
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.Postgrad Med. 2014 Jul;126(4):82-91. doi: 10.3810/pgm.2014.07.2786. Postgrad Med. 2014. PMID: 25141246
Cited by
-
Signaling pathways in rheumatoid arthritis: implications for targeted therapy.Signal Transduct Target Ther. 2023 Feb 17;8(1):68. doi: 10.1038/s41392-023-01331-9. Signal Transduct Target Ther. 2023. PMID: 36797236 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources